bioAffinity Technologies (BIAF) vs iSpecimen (ISPC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
bioAffinity Technologies is the larger company by market cap ($9.6 million vs $2.7 million), about 3.5 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | BIAF | ISPC |
|---|---|---|
| Share price | $8.26 | $1.09 |
| Market cap | $9.64M | $2.75M |
| 1-day change | +34.09% | -0.90% |
| EPS (TTM) | $-109.35 | $-52.98 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $80.70 | $40.04 |
| 52-week low | $4.56 | $1.02 |
| Distance from 52-week high | -89.76% | -97.28% |
| Average volume | 3.12M | 671.33K |
| Shares outstanding | 1.17M | 2.52M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Commercial Physical & Biological Resarch |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- bioAffinity Technologies is about 3.5 times larger than iSpecimen by market value ($9.64M vs $2.75M).
BIAF vs ISPC FAQ
Which is bigger, bioAffinity Technologies or iSpecimen?
bioAffinity Technologies (BIAF) is larger, with a market capitalization of $9.64M compared with $2.75M for iSpecimen (ISPC).
Are bioAffinity Technologies and iSpecimen in the same industry?
Yes. Both are classified in the Biotechnology: Commercial Physical & Biological Resarch industry within the Health Care sector.